-+ 0.00%
-+ 0.00%
-+ 0.00%

Otsuka Completes FDA Submission for Traditional Approval of Voyxact

PUBT·10/22/2026 14:03:37
Listen to the news
Otsuka Completes FDA Submission for Traditional Approval of Voyxact
  • Otsuka completed its supplemental biologics license application submission to the U.S. FDA seeking traditional approval of VOYXACT for IgA nephropathy.
  • Phase 3 results showed a 97.1% reduction in risk of kidney function decline or kidney failure versus placebo over two years.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Otsuka Holdings Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610221003BIZWIRE_USPR_____20261021_BW092821) on October 22, 2026, and is solely responsible for the information contained therein.